Ultragenyx Pharmaceutical (RARE) Stock Forecast & Price Target

Ultragenyx Pharmaceutical is supported by a durable orphan-drug franchise led by Crysvita, which has $2B+ global sales potential and currently contributes roughly one-quarter of profits under its KHK collaboration, while Dojolvi and Mepsevii add diversification across rare metabolic and lysosomal disorders. The company also has multiple near-term and medium-term catalysts, including the expected launch of Genglycos, a rare-disease PDUFA for UX111 on 9/19/26, and additional data readouts for UX701 in Q4:26 and DTX301 in H1:27, which could expand the commercial base further. Despite recent trial setbacks, its pipeline breadth across at least six indications, together with potential ~$400M in non-dilutive PRV proceeds and expanding territories for existing drugs, supports a constructive fundamental outlook.

Ultragenyx Pharmaceutical is facing a weak fundamental setup as 3Q26 revenue of $173M missed consensus and GAAP EPS of $(1.16) was slightly worse than expected, while management’s reliance on expense cuts underscores pressure on the commercial base rather than a clear growth inflection. The outlook remains negative because the company’s pipeline has been damaged by the UX701 termination and the ASPIRE Ph3 failure of GTX-102, which removed a major long-term growth driver and forced large revenue and OpEx revisions. With cash/equivalents of $401M at 3Q26, even before expected PRV proceeds, investors are left with limited near-term catalysts beyond setrusumab and the core products Crysvita, Dojolvi, and Mepsevii, making the shares likely to stay range bound.